当前位置: X-MOL 学术Thorac. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1
Thoracic Cancer ( IF 2.3 ) Pub Date : 2021-09-01 , DOI: 10.1111/1759-7714.14136
Wei Tian 1, 2 , Yinping Sun 2 , Yuping Cheng 2 , Xiao Ma 3 , Weina Du 4 , Wenna Shi 5 , Qisen Guo 6
Affiliation  

Recent studies have found that programmed death ligand 1 (PD-L1) might be involved in chemotherapy resistance in non-small cell lung cancer (NSCLC). Arsenic sulfide (As4S4) has been recognized to have antitumor activities and enhance the cytotoxic effect of chemotherapy drugs. In this study, we aimed to verify the relationship between PD-L1 and cisplatin (DDP) resistance and identify whether As4S4 could reverse DDP resistance through targeting PD-L1 in NSCLC.

中文翻译:

硫化砷通过靶向PD-L1在体外和体内逆转非小细胞肺癌顺铂耐药

最近的研究发现,程序性死亡配体 1 (PD-L1) 可能与非小细胞肺癌 (NSCLC) 的化疗耐药有关。硫化砷(As 4 S 4)已被公认为具有抗肿瘤活性并增强化疗药物的细胞毒作用。在本研究中,我们旨在验证 PD-L1 与顺铂 (DDP) 耐药之间的关系,并确定 As 4 S 4是否可以通过靶向 NSCLC 中的 PD-L1 来逆转 DDP 耐药。
更新日期:2021-10-04
down
wechat
bug